Literature DB >> 9499754

Practical issues regarding the use of antiretroviral therapy for HIV infection.

S G Deeks1.   

Abstract

With the recent development of potent new antiretroviral therapies, the management of HIV infection has become increasingly complex. There are now 12 antiretroviral drugs approved for use in the management of HIV infection, with several more in the advanced stages of clinical development. Staying current with this rapidly changing area of medicine is a challenge to clinicians caring for HIV-infected patients. This review provides an overview of HIV pathogenesis and discusses the basic principles of therapy. These principles, developed recently by the U.S. Department of Health and Human Services, provide a practical framework to rapidly incorporate new developments into clinical practice. Each of the three classes of antiretroviral therapies is then explained, focusing on the practical management of side effects, drug interactions, and viral resistance. The antiviral activity and clinical efficacy of each therapeutic class is reviewed, with an emphasis on applying current results to clinical decision making. Finally, recently published treatment guidelines are reviewed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9499754      PMCID: PMC1304849     

Source DB:  PubMed          Journal:  West J Med        ISSN: 0093-0415


  13 in total

1.  Crystalluria and urinary tract abnormalities associated with indinavir.

Authors:  J B Kopp; K D Miller; J A Mican; I M Feuerstein; E Vaughan; C Baker; L K Pannell; J Falloon
Journal:  Ann Intern Med       Date:  1997-07-15       Impact factor: 25.391

2.  Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients. A randomized, double-blind, controlled trial. Bristol-Myers Squibb Stavudine/019 Study Group.

Authors:  S L Spruance; A T Pavia; J W Mellors; R Murphy; J Gathe; E Stool; J G Jemsek; P Dellamonica; A Cross; L Dunkle
Journal:  Ann Intern Med       Date:  1997-03-01       Impact factor: 25.391

Review 3.  British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. BHIVA Guidelines Co-ordinating Committee.

Authors: 
Journal:  Lancet       Date:  1997-04-12       Impact factor: 79.321

4.  HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time.

Authors:  A S Perelson; A U Neumann; M Markowitz; J M Leonard; D D Ho
Journal:  Science       Date:  1996-03-15       Impact factor: 47.728

5.  HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy.

Authors:  J M Coffin
Journal:  Science       Date:  1995-01-27       Impact factor: 47.728

Review 6.  HIV-1 protease inhibitors. A review for clinicians.

Authors:  S G Deeks; M Smith; M Holodniy; J O Kahn
Journal:  JAMA       Date:  1997-01-08       Impact factor: 56.272

7.  A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team.

Authors:  S M Hammer; D A Katzenstein; M D Hughes; H Gundacker; R T Schooley; R H Haubrich; W K Henry; M M Lederman; J P Phair; M Niu; M S Hirsch; T C Merigan
Journal:  N Engl J Med       Date:  1996-10-10       Impact factor: 91.245

8.  A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group.

Authors:  J O Kahn; S W Lagakos; D D Richman; A Cross; C Pettinelli; S H Liou; M Brown; P A Volberding; C S Crumpacker; G Beall
Journal:  N Engl J Med       Date:  1992-08-27       Impact factor: 91.245

9.  Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators.

Authors:  R T D'Aquila; M D Hughes; V A Johnson; M A Fischl; J P Sommadossi; S H Liou; J Timpone; M Myers; N Basgoz; M Niu; M S Hirsch
Journal:  Ann Intern Med       Date:  1996-06-15       Impact factor: 25.391

10.  Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.

Authors:  P A Volberding; S W Lagakos; M A Koch; C Pettinelli; M W Myers; D K Booth; H H Balfour; R C Reichman; J A Bartlett; M S Hirsch
Journal:  N Engl J Med       Date:  1990-04-05       Impact factor: 91.245

View more
  2 in total

1.  Association of complementary and alternative medicine use with highly active antiretroviral therapy initiation.

Authors:  Daniel Merenstein; Yang Yang; Michael F Schneider; Lakshmi Goparaju; Kathleen Weber; Anjali Sharma; Alexandra M Levine; Gerald B Sharp; Monica Gandhi; Chenglong Liu
Journal:  Altern Ther Health Med       Date:  2008 Sep-Oct       Impact factor: 1.305

2.  An investigation of the possible interaction between the use of Vitamin C and highly active antiretroviral therapy (HAART) adherence and effectiveness in treated HIV+ women.

Authors:  Daniel Merenstein; Cuiwei Wang; Monica Gandhi; Esther Robison; Alexandra M Levine; Rebecca M Schwartz; Kathleen M Weber; Chenglong Liu
Journal:  Complement Ther Med       Date:  2012-04-08       Impact factor: 2.446

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.